Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Tecvayli
Pharma
J&J reports $133M in sales for new multiple myeloma med Tecvayli
For the first time, J&J is reporting sales of Tecvayli, which is off to a strong launch and contributing to the company's power in multiple myeloma.
Kevin Dunleavy
Apr 16, 2024 11:28am
CAR-T hype faces infrastructure reality check
Jan 15, 2024 3:00am
JPM24: J&J CEO thinks key launches can outdo analyst estimates
Jan 8, 2024 3:11pm
ASH: Study digs into FDA adverse event record of BCMA therapies
Dec 11, 2023 2:46am
J&J expects 25 blockbuster drugs to drive future sales growth
Dec 5, 2023 4:42pm
J&J touts progress on new launches as Stelara cliff nears
Oct 17, 2023 10:15am
